Antibody Information
General Information of This Antibody (ID: ANTI0HDKYR)
| Antibody Name | A humanized anti-EGFR IgG1 mAb |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | EGFR |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HLX42 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants (18-75 years) must have confirmed advanced/metastatic solid tumors, measurable lesions per RECIST 1.1, ECOG 0-1, and adequate organ function. Exclusions include recent malignancies, uncontrolled ILD, allergies to study drug components, active infections, poorly managed cardiovascular issues, immunosuppressive therapy, or hepatic dysfunction (except Child-Pugh A in HCC). Pregnant/nursing women or those deemed unsuitable by investigators are excluded.
Click to Show/Hide
|
||||
| Administration Dosage |
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06210815 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX42 (Anti-EGFR ADC) in Patients With Advanced/Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The study evaluates HLX42's Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) within 21 days post-first administration. DLT includes drug-related AEs impacting dose escalation, while MTD is the highest dose where ≤1 of 6 patients experience DLT.
|
||||
| Other Endpoint |
Primary and secondary endpoints include Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) over approximately 24 months. Pharmacokinetic measures (Cmax, Tmax, T1/2) are assessed within 21 days, alongside immune responses (ADA, Nab incidence/titer). Treatment-emergent adverse events are monitored until 90 days post-last dose.
Click to Show/Hide
|
||||